Abstract
More than 90% of cancer deaths are caused by cancer metastasis. Since cancer metastasis is the main cause of human deaths, so in this article more attention will be paid to it than ever before. Presently, clinical cancer chemotherapies have been targeting on primary tumors rather than on metastatic processes. Since the antimetastatic drugs are different from antiproliferative drugs and underinvestigated, cancer patients’ survival has been improved on a small scale now. To change this stalemate, this problem is reiterated by an analysis of the relationship between pathology, pharmacology and clinical therapy of neoplasm metastasis and it is suggested to improve the outcome of chemotherapy of cancer patients from different possible ways; e.g. to make more efforts to manufacture new types of antimetastatic drugs and optimize use of these drugs in clinics.
Keywords: Cancer chemotherapy, cancer medicinal chemistry, cancer treatment, cancer pathology, cancer pharmacology, neoplasm metastases.
Current Drug Therapy
Title:Cancer Metastasis Treatments
Volume: 8 Issue: 1
Author(s): Da-Yong Lu, Ting-Ren Lu, Hong-Ying Wu and Shan Cao
Affiliation:
Keywords: Cancer chemotherapy, cancer medicinal chemistry, cancer treatment, cancer pathology, cancer pharmacology, neoplasm metastases.
Abstract: More than 90% of cancer deaths are caused by cancer metastasis. Since cancer metastasis is the main cause of human deaths, so in this article more attention will be paid to it than ever before. Presently, clinical cancer chemotherapies have been targeting on primary tumors rather than on metastatic processes. Since the antimetastatic drugs are different from antiproliferative drugs and underinvestigated, cancer patients’ survival has been improved on a small scale now. To change this stalemate, this problem is reiterated by an analysis of the relationship between pathology, pharmacology and clinical therapy of neoplasm metastasis and it is suggested to improve the outcome of chemotherapy of cancer patients from different possible ways; e.g. to make more efforts to manufacture new types of antimetastatic drugs and optimize use of these drugs in clinics.
Export Options
About this article
Cite this article as:
Lu Da-Yong, Lu Ting-Ren, Wu Hong-Ying and Cao Shan, Cancer Metastasis Treatments, Current Drug Therapy 2013; 8 (1) . https://dx.doi.org/10.2174/1574885511308010003
DOI https://dx.doi.org/10.2174/1574885511308010003 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Emerging Role of CSN6 in Biological Behavior and Cancer Progress
Anti-Cancer Agents in Medicinal Chemistry Pharmacologic Inhibition of mTOR Improves Lapatinib Sensitivity in HER2-Overexpressing Breast Cancer Cells with Primary Trastuzumab Resistance
Anti-Cancer Agents in Medicinal Chemistry The Effect of Tumour Necrosis Factor-α on Periodontal Ligament Stem Cell Differentiation and the Related Signaling Pathways
Current Stem Cell Research & Therapy Renal and Hepatic Transporter Expression in Type 2 Diabetic Rats
Drug Metabolism Letters Biochemical Properties of Indoleamine 2,3-dioxygenase: From Structure to Optimized Design of Inhibitors
Current Medicinal Chemistry Recent Patents on Imaging Nanoprobes for Brain Tumor Diagnosis and Therapy
Recent Patents on Biotechnology Epidermal Growth Factor Receptor Inhibitors: A New Prospective in the Treatment of Lung Cancer
Current Medicinal Chemistry - Anti-Cancer Agents Molecular Dynamics and Biological Evaluation of 2-chloro-7-cyclopentyl- 7H-pyrrolo[2,3-d]pyrimidine Derivatives Against Breast Cancer
Combinatorial Chemistry & High Throughput Screening Current Progress of Reelin in Development, Inflammation and Tissue Remodeling: From Nervous to Visual Systems
Current Molecular Medicine Unveiling the Transient Protein-Protein Interactions that Regulate the Activity of Human Lemur Tyrosine Kinase-3 (LMTK3) Domain by Cyclin Dependent Kinase 5 (CDK5) in Breast Cancer: An in silico Study
Current Proteomics Cancer Cell Permeability-Glycoprotein as a Target of MDR Reverters: Possible Role of Novel Dihydropyridine Derivatives
Current Drug Targets Targeted Therapy of Breast Cancer
Current Pharmaceutical Design Strategies for Non-Invasive Molecular Imaging of Acute Allograft Rejection by Gamma Scintigraphy and Positron Emission Tomography
Current Radiopharmaceuticals Quantum Dots in the Therapy: Current Trends and Perspectives
Mini-Reviews in Medicinal Chemistry Exosome-Encapsulated microRNAs as Potential Circulating Biomarkers in Colon Cancer
Current Pharmaceutical Design Inhibitory Smad7: Emerging Roles in Health and Disease
Current Molecular Pharmacology Synthesis of Combretastatin A-4 Analogs and their Biological Activities
Anti-Cancer Agents in Medicinal Chemistry EGFR(S) Inhibitors in the Treatment of Gastro-Intestinal Cancers: Whats New?
Current Drug Targets Systems Biology and Synthetic Biology: Understanding Biological Complexity on the Critical Path to Personalized Medicine
Current Pharmacogenomics and Personalized Medicine Cytarabine and Ferric Carboxymaltose (Fe+3) Increase Oxidative Damage and Alter Serotonergic Metabolism in Brain
CNS & Neurological Disorders - Drug Targets